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Abstract
Background: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres after cell
division and maintains chromosomal length and stability thus leading to cellular immortalisation.
The hTERT (human telomerase reverse transcriptase) subunit seems to be the rate-limiting
determinant of telomerase and knowledge of factors controlling hTERT transcription may be useful
in therapeutic strategies. The hTERT promoter contains binding sites for c-Myc and there is
experimental and in vitro evidence that c-Myc may increase hTERT expression.
Materials and methods: RNA was extracted from 18 breast carcinomas and c-Myc mRNA
expression was estimated by quantitative reverse transcriptase-PCR (RT-PCR) with Taqman
methodology. These tumours had already been analysed for ER and PgR status using ligand-binding
assays and had had their DNA ploidy and S-phase fractions measured by flow cytometry.
Telomerase activity had already been determined by using a modified telomeric repeat and
amplification protocol (TRAP) assay.
Results: Telomerase activity ranged from 0 to 246 units of Total Protein Generated (TPG), where
one unit of TPG was equal to 600 molecules of telomerase substrate primers extended by at least
three telomeric repeats. Median levels of TPG were 60 and mean levels 81. There was no significant
correlation between levels of c-Myc mRNA expression, telomerase activity, S phase fraction or
PgR. There was a significant negative correlation with ER status.
Conclusion: Although the hTERT promoter contains potential binding sites for c-Myc
oncoprotein, we have found no correlation between c-Myc mRNA levels and telomerase activity.
Introduction
Telomerase is a multi-component ribonucleoprotein
located within the nucleus, the function of which is to
synthesise the repetitive nucleotide sequence forming the
telomeres at the end of chromosomes [1]. During cell
division, DNA polymerase is unable to fully replicate the
ends of linear DNA and genetic material is lost which
eventually can result in chromosome instability and cellu-
lar senescence. Telomerase synthesises a new copy of the
telomere repeat [1] so that cellular proliferation can con-
tinue leading to cellular immortality [2,3]. Telomerase is
active in 70 – 90% of malignant tissues and many
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able telomerase activity. Telomerase activity has been
shown in some cancers to correlate with prognostic varia-
bles [4,5]. We detected telomerase activity in 74% of inva-
sive breast cancers and in none of benign or normal breast
tissue specimens. Furthermore, we observed a correlation
between telomerase activity and tumour size, nodal sta-
tus, lymphovascular invasion and Ki-67 expression [6,7].
The fundamental components of telomerase have been
identified as the RNA template (hTR), the reverse tran-
scriptase (hTERT) and telomerase associated proteins,
including (TEP1) [1,8,9]. Of these hTR and TEP1 are
expressed ubiquitously in both normal and cancerous tis-
sue [8], whereas hTERT is detectable in tumour cells but
not in normal somatic cells [9-11]. Telomerase enzyme
activity can be reconstituted in fibroblasts by the ectopic
expression of hTERT [12] and induction of hTERT expres-
sion has been shown to be essential for telomerase activa-
tion in cell-lines [9,10]. These observations suggest that
hTERT is the rate-limiting determinant of telomerase
enzyme activity. We have recently reported that hTERT
mRNA is much higher in breast cancer specimens com-
pared with adjacent non-cancerous breast tissue [13] and
that telomerase activity is significantly correlated with
hTERT mRNA expression [14]. Investigation of the mech-
anisms of hTERT control is important in elucidating the
pathways that may be amenable to therapeutic manipula-
tion and one such pathway involves the transcription fac-
tor Myc.
An increased level of c-Myc occurs frequently in a wide
range of tumours [15,16] due to de-regulated expression
of myc through gene amplification, retroviral insertion or
chromosomal translocation. Sequence analysis of the
hTERT gene promoter has shown the presence of at least 2
[17] and perhaps as many as 29 E boxes [18], potential
binding sites for the Myc oncoprotein, and the possibility
of a regulatory role for Myc has been explored in a number
of studies. It has been found that purified Myc interacts
with the E box sequences and that cotransfection of Myc
induces activity in the isolated hTERT promoter [19]. It
has been shown that retroviral expression of c-myc
increases the amount of hTERT mRNA in human mam-
mary epithelial cells and fibroblasts and telomerase activ-
ity could thereafter be detected [20]. It has also been
reported that expression of c-Myc leads to increased
hTERT expression and telomerase activity in human B
cells [21]. Moreover, since this does not require protein
synthesis this appears to be due to a direct effect of Myc on
the hTERT promoter and not secondary to an increase in
cellular proliferation by Myc [21]. In addition, the intro-
duction of Myc anti-sense RNA has been shown to lead to
a reduction in hTERT promoter activity [19].
Our aim in this study was to investigate whether the level
of c-Myc mRNA expression correlates with telomerase
activity in human breast carcinomas.
Materials and methods
Local ethical approval was obtained. Specimens of human
breast carcinoma tissue (n = 18) were acquired from the
MD Anderson centre (Texas, USA). These had been ana-
lysed already for quantitative telomerase activity (using a
variation on the TRAP assay), ER (ER+ = ≥3 fmol/mg pro-
tein), PgR, (PgR+ = ≥5 fmol/mg protein), S-phase fraction
(<6% = low, 6–10% = intermediate, >10% = high}DNA
and ploidy status (diploid or aneuploid), by this unit as
described previously [22].
RNA extraction
Total cellular RNA was extracted from 10–20 mg of these
tumours using the RNeasy Mini isolation kit (Qiagen,
Hilden, Germany) according to the manufacturer's proto-
col. Quantification of the RNA following treatment with
DNase (Promega) was carried out in triplicate using the
RiboGreen reagent (Molecular Probes Europe BV) accord-
ing to the manufacturers protocol.
RT-PCR
TaqMan RT-PCR was performed in duplicate for each
sample using the ABI PRISM 7700 Sequence Detector
(Perkin-Elmer Applied Biosystems) and the TaqMan EZ
RT-PCR Core Reagents Kit (Perkin-Elmer Applied Biosys-
tems). The RT-PCR was performed for c-Myc using the for-
ward and reverse oligonucleotide primers and TaqMan
probes given in Table 1. These oligonucleotides were
TRAP assay results showing telomerase positive and telom-erase neg tiv  samplesFigure 1
TRAP assay results showing telomerase positive and telom-
erase negative samples. Positivity is indicated by the presence 
of a DNA ladder after electrophoresis on a polyacrylamide 
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systems, Warrington, UK) using gene sequences obtained
from the GenBank database. Primers and probe were
intron spanning to prevent amplification of genomic
DNA and define a 71 base pair amplicon crossing from
exons 2 to 3 in the c-myc gene (accession number
V00568.1)
Conditions for the reverse transcription step were 50°C
for 2 minutes, 60°C for 10 minutes, and 92°C for 5 min-
utes. The polymerase chain reaction was carried out for 50
cycles of 20 seconds at 92°C and 25 seconds at 62°C. For
the negative control RNase free water was used in the RT-
PCR mix instead of RNA. For the positive control, the
amplicon of C-Myc was used. A standard curve for c-Myc
was constructed using serial dilutions of a single stranded
sense oligonucleotide specifying the amplicon as previ-
ously described by Bustin et al [23] and this together with
the known RNA concentration was used to quantify the
mRNA copy number per microgram of RNA.
Results and statistical analysis
Telomerase activity varied between 0 and 246 units of
Total Protein Generated (TPG), where one unit of TPG
Table 1: Sequences of TaqMan Primers and Probes for RT-PCR.
Gene Forward Reverse Probe
c-Myc 5'TGA GGA GAC ACC GCCCAC3' 5'CAA CAT CGA TTTCTT CCT CAT CTT C3' 5'CCA GCA GCG ACT CTG AGG AGG AAC A3'
Table 2: The relationships between c-Myc mRNA expression and, ER, PgR, ploidy and SPF using Kruskal-Wallis p-values.
factor N Mean SD Median p-value
cmyc
ER- 17 69580146 61984126 40202108 0.63
ER+ 1 63344107 . .
PgR- 10 59102005 59941659 38086495 0.21
PgR+ 8 81898317 61947631 74842241
Diploid 9 1.0277E8 68918774 86487036 0.038
Aneuploid 9 35698918 20212590 39212925
LowSPF 9 85567170 55632400 86340375 0.34
IntermediateSPF 3 79641669 117177069 23457155
HighSPF 6 39529509 15928240 39707516
Table 3: Spearman correlation coefficients (SCCs) demonstrating no significant correlation between c-Myc mRNA expression and TPG 
by telomerase. However there is a significant correlation between hTERT mRNA expression and TPG and between c-Myc and absence 
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ers extended by at least three telomeric repeats [figure 1].
Median levels of TPG were 60 and mean levels 81. C-Myc
mRNA levels were between 1.14 × 106 and 2.14 × 108
(mean 6.92 × 107) copy numbers per µg of RNA. Statisti-
cal analysis was performed using SAS (Version 6.11, SAS
Institute, Cary, North Carolina). The C-Myc expression,
ER, PgR, S-phase fraction and telomerase activity were
considered as continuous variables and the relationship
between them was investigated using Spearman's nonpar-
ametric correlation coefficient. No significant relationship
was found between C-Myc expression and telomerase
activity (rs = 0.05691, p = 0.8225), [figure 2]. C-Myc
mRNA expression was however, found to be inversely cor-
related with ER status (rs = -0.52583, p = 0.0250) but not
to correlate with PgR status (rs = -0.149, p = 0.55) or S
phase fraction (rs= -0.334, p = 0.1708).
We also examined whether there are any differences in c-
Myc mRNA expression by ER status (ER+ = ≥3 fmol/
mgprotein), PgRstatus (PgR+ = ≥5 fmol/mg protein),
DNA ploidy status (diploid or aneuploid), S-phase frac-
tion (<6% = low, 6–10% = intermediate, >10% = high)
and observed a strong relationship was observed between
c-Myc mRNA expression and diploidy (p = 0.03) [Tables
2, 3].
Conclusion
Although the hTERT promoter contains E-boxes, we have
found no correlation between c-Myc mRNA levels and tel-
omerase activity.
The control of hTERT is undoubtedly a complex one and
it is likely that a number of other transcription factors
influence its expression than c-Myc. These might act
together with c-Myc, as has been shown for Sp1 [24] or
independently. In this respect, it has been shown that
transfer of a normal chromosome 3 into human breast
carcinoma cells results in abolition of hTERT transcripts
without any change in c-Myc levels [25]. Furthermore, it is
known that another member of the Myc family, Mad1
forms a complex with Max and acts as a transcriptional
repressor at the same binding sites as Myc-Max [16]. It has
been shown that, the proportion of Mad1 binding to the
hTERT promoter rises and that of Myc falls, during the dif-
ferentiation of HL60 cells [26]. This is associated with
reduced acetylation of the hTERT promoter and measure-
ment of the Mad/Myc ratio is likely to be important in
establishing the overall level of transcriptional activation
of hTERT.
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